IRIS

Indeno[1,2,3-cd]pyrene

CASRN 193-39-5

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (9 pp, 102 K)
Not assessed under the IRIS Program.

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (9 pp, 102 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (9 pp, 102 K) last updated: 12/01/1990

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on no human data and sufficient data from animal bioassays. Indeno[1,2,3-cd]pyrene produced tumors in mice following lung implants, subcutaneous injection and dermal exposure. Indeno[1,2,3-cd]pyrene tested positive in bacterial gene mutation assays.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (9 pp, 102 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (9 pp, 102 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.